Showing 1061-1070 of 20877 results for "".
- Multicomponent Maternal Sepsis Program Lowers Infection Eventshttps://reachmd.com/news/multicomponent-maternal-sepsis-program-lowers-infection-events/2487425/Key Takeaways The APT-Sepsis program was associated with a lower rate of the primary composite maternal infection outcome than usual care. The reported effect was generally similar across both countries and facility sizes and was described as sustained
- Rifaximin Improves Cognitive Performance in Covert Hepatic Encephalopathyhttps://reachmd.com/news/rifaximin-improves-cognitive-performance-in-covert-hepatic-encephalopathy/2487439/Key Takeaways Rifaximin was associated with significant within-group improvement on the Stroop test over 12 weeks in this randomized trial. The between-group change favored rifaximin overall and remained at trend level, while a baseline subgroup withou
- LLM Chatbot Conversations and Parental HPV Vaccine Intentions in a Trialhttps://reachmd.com/news/llm-chatbot-conversations-and-parental-hpv-vaccine-intentions-in-a-trial/2487432/Key Takeaways All active study arms were associated with higher immediate HPV vaccination intention than no message, with public health materials showing the largest increase. At 15 days, public health materials and the conversational chatbot still sho
- Oral PCSK9 Inhibitor Enlicitide Lowers LDL Cholesterol In Phase 3 Trialhttps://reachmd.com/news/oral-pcsk9-inhibitor-enlicitide-lowers-ldl-cholesterol-in-phase-3-trial/2487434/Key Takeaways Enlicitide was associated with a marked week 24 LDL cholesterol reduction, while placebo showed little change over the same interval. Week 52 LDL cholesterol and week 24 non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) also favor
- Atrasentan Shows Long-Term Kidney Benefit in IgA Nephropathyhttps://reachmd.com/news/atrasentan-shows-long-term-kidney-benefit-in-iga-nephropathy/2487433/Key Takeaways In the main stratum, atrasentan was associated with a smaller eGFR decline over 2.5 years than placebo. An exploratory stratum that included participants receiving an SGLT2 inhibitor also showed a between-group eGFR difference favoring at
- Robot-Assisted Versus Conventional Minimally Invasive Oesophagectomyhttps://reachmd.com/news/robot-assisted-versus-conventional-minimally-invasive-oesophagectomy/2487440/Key Takeaways Five-year overall survival was higher with robot-assisted surgery, and the prespecified non-inferiority criterion was met; an exploratory superiority analysis gave p=0.032. The trial randomly assigned 362 patients in a 1:1 ratio across si
- Small Bites Versus Large Bites in Midline Incision Closurehttps://reachmd.com/news/small-bites-versus-large-bites-in-midline-incision-closure/2487441/Key Takeaways At 13 years, cumulative incisional hernia incidence was 34% with small bites and 49% with large bites. Incisional hernias wider than 20 mm were less frequent after small-bites closure, occurring in 17% versus 34% of patients. Her
- Telitacicept Interim Phase 3 Trial in IgA Nephropathyhttps://reachmd.com/news/telitacicept-iga-nephropathy/2487417/Key Takeaways Telitacicept was associated with a larger reduction in proteinuria than placebo at the interim 39-week assessment. Estimated glomerular filtration rate declined less with telitacicept than with placebo over the reported follow-up.
- Whole Health Team Improved Pain Interference In VA Trialhttps://reachmd.com/news/whole-health-pain-interference-va/2487415/Key Takeaways The Whole Health arm was associated with greater improvement in 12-month pain interference than either comparator. Group cognitive behavioral therapy was not significantly different from usual care on the primary endpoint. Suicid
- Tumor-Informed ctDNA Stratifies Risk in Anal Squamous Cell Carcinomahttps://reachmd.com/news/tumor-informed-ctdna-stratifies-risk-in-anal-squamous-cell-carcinoma/2487405/Key Takeaways End-of-treatment ctDNA positivity was associated with worse 1-year overall survival, progression-free survival, and locoregional failure, including 96% versus 63% overall survival and 92% versus 44% progression-free survival for ctDNA-negative ver